PL2329848T5 - Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2 - Google Patents

Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2

Info

Publication number
PL2329848T5
PL2329848T5 PL09175877T PL09175877T PL2329848T5 PL 2329848 T5 PL2329848 T5 PL 2329848T5 PL 09175877 T PL09175877 T PL 09175877T PL 09175877 T PL09175877 T PL 09175877T PL 2329848 T5 PL2329848 T5 PL 2329848T5
Authority
PL
Poland
Prior art keywords
lixisenatide
metformin
diabetes
therapy
add
Prior art date
Application number
PL09175877T
Other languages
English (en)
Other versions
PL2329848T3 (pl
Inventor
Louise Silvestre
Elisabeth Souhami
Xiaodan Wei
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41800749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2329848(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of PL2329848T3 publication Critical patent/PL2329848T3/pl
Publication of PL2329848T5 publication Critical patent/PL2329848T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09175877T 2009-11-13 2009-11-13 Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2 PL2329848T5 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09175877.1A EP2329848B2 (en) 2009-11-13 2009-11-13 Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes

Publications (2)

Publication Number Publication Date
PL2329848T3 PL2329848T3 (pl) 2013-05-31
PL2329848T5 true PL2329848T5 (pl) 2019-12-31

Family

ID=41800749

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09175877T PL2329848T5 (pl) 2009-11-13 2009-11-13 Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2

Country Status (11)

Country Link
EP (1) EP2329848B2 (pl)
CY (1) CY1113755T1 (pl)
DK (1) DK2329848T4 (pl)
ES (1) ES2398012T5 (pl)
HR (1) HRP20121029T4 (pl)
ME (1) ME01546B (pl)
PL (1) PL2329848T5 (pl)
PT (1) PT2329848E (pl)
RS (1) RS52629B2 (pl)
SI (1) SI2329848T2 (pl)
SM (1) SMT201300013B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
CN103458919A (zh) * 2011-02-02 2013-12-18 赛诺菲-安万特德国有限公司 在2型糖尿病患者中预防低血糖症
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2771024B1 (en) * 2011-10-28 2018-11-28 Sanofi-Aventis Deutschland GmbH Treatment protocol of diabetes type 2
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
SG11201509781YA (en) * 2013-06-17 2015-12-30 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels

Also Published As

Publication number Publication date
SI2329848T2 (sl) 2019-10-30
DK2329848T3 (da) 2013-02-04
RS52629B2 (sr) 2019-11-29
ME01546B (me) 2014-04-20
SMT201300013B (it) 2013-03-08
HRP20121029T4 (hr) 2019-10-18
EP2329848B2 (en) 2019-06-19
PL2329848T3 (pl) 2013-05-31
EP2329848A1 (en) 2011-06-08
EP2329848B1 (en) 2012-10-24
RS52629B (en) 2013-06-28
SI2329848T1 (sl) 2013-02-28
ES2398012T5 (es) 2020-02-26
CY1113755T1 (el) 2016-07-27
DK2329848T4 (da) 2019-09-09
ES2398012T3 (es) 2013-03-13
HRP20121029T1 (hr) 2013-01-31
PT2329848E (pt) 2013-01-23

Similar Documents

Publication Publication Date Title
HRP20121029T1 (hr) Liksisenatid kao pomoä†na terapija uz inzulin glargin i metformin kod lijeäśenja dijabetesa tip 2
HRP20170209T1 (hr) Liksisenatid kao dodatna terapija uz bazalni inzulin kod dijabetesa tipa 2
SI2324853T1 (sl) Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2
IL219945A (en) 1-GLP history with dual transduction and use of it to prepare a drug for the treatment of diabetes
IL250549A0 (en) Acetyl analogs of insulin that are resistant to protease and their use for the preparation of a drug for the treatment and prevention of diabetes
IL209887A0 (en) Treatment for diabetes in patients inappropriate for metformin therapy
IL212903A0 (en) Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
HK1164112A1 (en) Treating hyperglycemia with glp-1 glp-1
PT2707017E (pt) Lixisenatida e metformina para tratamento da diabetes tipo 2
PL2611458T3 (pl) Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
PT2459207E (pt) Composição farmacêutica para tratamento de condições médicas e um método para tratamento de distúrbios alimentares e doenças relacionadas
ZA201105094B (en) Combination of insulin with triazine derivatives and its use for treating diabetes
GB0919603D0 (en) Use of thymosin beta-4 for treatment of type II diabetes
ZA201008998B (en) Treatment for diabetes in patients inappropriate for metformin therapy
EG27140A (en) Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
ZA200909123B (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome
GB0912906D0 (en) Treatment of diabetes and metabolic syndrome
GB0910904D0 (en) Treatment of diabetes and metabolic syndrome
GB0904271D0 (en) Treatment of diabetes and metabolic syndrome